CR20150371A - Inhibidores de prmt5 y sus usos - Google Patents

Inhibidores de prmt5 y sus usos

Info

Publication number
CR20150371A
CR20150371A CR20150371A CR20150371A CR20150371A CR 20150371 A CR20150371 A CR 20150371A CR 20150371 A CR20150371 A CR 20150371A CR 20150371 A CR20150371 A CR 20150371A CR 20150371 A CR20150371 A CR 20150371A
Authority
CR
Costa Rica
Prior art keywords
compounds
prmt5
prmt5 inhibitors
inhibitors
inhibition
Prior art date
Application number
CR20150371A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth W Duncan
Richard Chesworth
Paula Ann Boriack-Sjodin
Michael John Munchhof
Lei Jin
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49958717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CR20150371A publication Critical patent/CR20150371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20150371A 2012-12-21 2015-07-13 Inhibidores de prmt5 y sus usos CR20150371A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745485P 2012-12-21 2012-12-21
US201361790525P 2013-03-15 2013-03-15
PCT/US2013/077235 WO2014100719A2 (en) 2012-12-21 2013-12-20 Prmt5 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CR20150371A true CR20150371A (es) 2015-11-09

Family

ID=49958717

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150371A CR20150371A (es) 2012-12-21 2015-07-13 Inhibidores de prmt5 y sus usos

Country Status (31)

Country Link
US (10) US8993555B2 (enExample)
EP (3) EP2935222B1 (enExample)
JP (1) JP6678455B2 (enExample)
KR (2) KR102024417B1 (enExample)
CN (1) CN105452226B (enExample)
AU (1) AU2018202150B2 (enExample)
BR (1) BR112015014590B1 (enExample)
CA (1) CA2894228C (enExample)
CL (1) CL2015001790A1 (enExample)
CR (1) CR20150371A (enExample)
CY (1) CY1121625T1 (enExample)
DK (1) DK2935222T3 (enExample)
DO (1) DOP2015000158A (enExample)
EA (1) EA027908B1 (enExample)
ES (1) ES2701069T3 (enExample)
HR (1) HRP20182037T1 (enExample)
HU (1) HUE040323T2 (enExample)
IL (3) IL239296B (enExample)
LT (1) LT2935222T (enExample)
MX (1) MX375184B (enExample)
MY (1) MY199894A (enExample)
PE (1) PE20151501A1 (enExample)
PH (2) PH12015501351A1 (enExample)
PL (1) PL2935222T3 (enExample)
PT (1) PT2935222T (enExample)
RS (1) RS58040B1 (enExample)
SI (1) SI2935222T1 (enExample)
SM (1) SMT201800669T1 (enExample)
UA (1) UA118548C2 (enExample)
WO (1) WO2014100719A2 (enExample)
ZA (1) ZA201505212B (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9288251B2 (en) * 2011-06-10 2016-03-15 Citrix Systems, Inc. Adaptive bitrate management on progressive download with indexed media files
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
ES2865402T3 (es) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HUE050215T2 (hu) 2013-01-15 2020-11-30 Incyte Holdings Corp Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR20160003647A (ko) 2013-03-15 2016-01-11 에피자임, 인코포레이티드 Carm1 억제제 및 이의 용도
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP6559719B2 (ja) 2014-06-25 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CA2953572A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3189048B1 (en) * 2014-09-03 2021-03-17 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN105497034B (zh) * 2015-12-08 2018-08-07 暨南大学 一种通过靶向prmt5抑制骨肉瘤生长的组合物及其制备方法
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
MX374813B (es) 2016-03-10 2025-03-06 Janssen Pharmaceutica Nv Análogos de nucleósidos sustituidos para su uso como inhibidores de prmt5.
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP7101171B2 (ja) 2016-10-03 2022-07-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
AU2017348322B8 (en) 2016-10-28 2021-12-23 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating EZH2-mediated cancer
AU2017367300A1 (en) 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN110234342A (zh) * 2016-12-01 2019-09-13 葛兰素史密斯克莱知识产权发展有限公司 组合疗法
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018161922A1 (zh) * 2017-03-09 2018-09-13 中国科学院上海药物研究所 一种具有prmt5抑制活性的化合物及其制备和应用
GB201704327D0 (en) * 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
BR112020002736A2 (pt) * 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
EP3706742B1 (en) * 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
HUE067265T2 (hu) * 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
MA51004A (fr) 2017-12-08 2020-10-14 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
UA126349C2 (uk) 2017-12-13 2022-09-21 Люпін Лімітед Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
HUE059624T2 (hu) 2018-02-20 2022-11-28 Incyte Corp N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
EP3755317A4 (en) * 2018-02-22 2022-02-23 Icahn School of Medicine at Mount Sinai COMPOUNDS DEGRADING/DESTRUCTING PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AND METHODS OF USE
WO2019173516A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
JP7092895B2 (ja) 2018-03-09 2022-06-28 南京薬石科技股▲フン▼有限公司 タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の阻害剤、その医薬品及びその方法
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
DK3765461T3 (da) * 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
CA3092770A1 (en) * 2018-03-22 2019-09-26 Aurigene Discovery Technologies Limited Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
EP3768670A4 (en) * 2018-03-22 2021-11-24 Aurigene Discovery Technologies Limited IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS
WO2019219805A1 (en) 2018-05-16 2019-11-21 Ctxone Pty Ltd Combination therapy
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
BR112021007823A2 (pt) * 2018-11-08 2021-07-27 Glaxosmithkline Intellectual Property Development Limited combinação de inibidores da prmt5 e inibidores do bcl-2
WO2020182018A1 (zh) * 2019-03-12 2020-09-17 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
US20230212143A9 (en) * 2019-03-29 2023-07-06 University Of Florida Research Foundation, Incorporated Prmt5 inhibitor compounds
CN111825656B (zh) * 2019-04-15 2023-03-31 南京药石科技股份有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的抑制剂、其药学产品及其方法
WO2020227325A1 (en) 2019-05-06 2020-11-12 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
US12391695B2 (en) 2019-06-10 2025-08-19 Lupin Limited PRMT5 inhibitors
EP3983393B1 (en) 2019-06-12 2025-04-02 Janssen Pharmaceutica NV Novel spirobicyclic intermediates
KR20220027216A (ko) 2019-06-28 2022-03-07 에이엘에스 테라피 디벨럽먼트 인스티튜트 디펩타이드 반복 단백질의 억제
CN110585434B (zh) * 2019-10-11 2021-04-09 山东大学 Prmt5抑制剂在抗病毒中的应用
EP4043459A4 (en) 2019-10-12 2022-12-21 Nanjing Sanhome Pharmaceutical Co., Ltd. SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOF
KR20220086628A (ko) 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN112778275B (zh) * 2019-11-11 2023-05-12 石药集团中奇制药技术（石家庄）有限公司 金刚烷基prmt5抑制剂及其应用
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
CN111018832A (zh) * 2019-11-26 2020-04-17 济南大学 一类含有四氢异喹啉结构的咪唑酮类化合物的制备及应用
KR102514245B1 (ko) * 2019-12-03 2023-03-29 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도
WO2021111322A1 (en) 2019-12-03 2021-06-10 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
US20230108452A1 (en) * 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
WO2021126728A1 (en) * 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
IL293965A (en) 2019-12-19 2022-08-01 Janssen Pharmaceutica Nv History of Spiro straight chain transformed
CN113045543B (zh) * 2019-12-26 2023-05-12 石药集团中奇制药技术（石家庄）有限公司 一种prmt5抑制剂及其应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN113754541B (zh) * 2020-06-02 2025-01-03 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
CA3174311A1 (en) * 2020-06-02 2021-12-09 Chuanwu ZHAO 3,4-dihydroisoquinoline compound and use thereof
CN111592522B (zh) * 2020-06-17 2022-09-09 郑州大学 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
IL300147A (en) 2020-07-31 2023-03-01 Tango Therapeutics Inc History Piperidin-1-yl-N-pyridin-3-yl-2-oxaacetamide is useful for the treatment of MTAP-deficient and/or MTA-accumulating cancer
EP4209485A4 (en) * 2020-09-04 2025-02-19 Innovstone Therapeutics Limited ASSOCIATES WITH ANTI-TUMOOR ACTIVITY AND USE THEREOF
CN116134034A (zh) * 2020-09-22 2023-05-16 南京明德新药研发有限公司 四氢异喹啉衍生物及其应用
AU2022271927B2 (en) 2021-05-13 2025-07-10 Innovstone Therapeutics Limited Compound having anti-tumor activity and use thereof
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
EP4446317A4 (en) * 2021-12-08 2025-09-17 Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND ITS USE
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN119101034B (zh) * 2023-06-07 2025-10-17 石药集团中奇制药技术（石家庄）有限公司 固体形式的3,4-二氢异喹啉类化合物及其制备方法和用途
CN119101035B (zh) * 2023-06-07 2025-10-17 石药集团中奇制药技术（石家庄）有限公司 3,4-二氢异喹啉类化合物的盐及其制备方法和用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD68906A (enExample)
DE63776C (de) A. RUPERT, Eisenbahn - Werkmeister, in Köln - Nippes, Escherstrafse 14 Verfahren und Vorrichtung eiserne Rohrwände mit Messing zu überziehen
GB1374366A (en) 1972-07-21 1974-11-20 Science Union & Cie Propanol derivatives and a process for their preparation
DE2361390A1 (de) * 1973-12-10 1975-06-19 Merck Patent Gmbh Isochinolinderivate und verfahren zu ihrer herstellung
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
CA1072359A (en) 1974-10-08 1980-02-26 Hiroyuki Konishi Method for controlling the growth of plants
HU179951B (en) 1979-10-11 1983-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
JPS595185A (ja) 1982-06-16 1984-01-12 メイ・アンド・ベイガ−・リミテツド 新規なピラゾロピリジン誘導体
DE3303344A1 (de) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern
US4684459A (en) 1985-11-29 1987-08-04 The Dow Chemical Company Collector compositions for the froth flotation of mineral values
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPH07100688B2 (ja) * 1986-02-12 1995-11-01 大日本製薬株式会社 環状アミン誘導体
DE3631013A1 (de) * 1986-09-12 1988-03-24 Thomae Gmbh Dr K Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3640641A1 (de) 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE3804793A1 (de) 1988-02-16 1989-08-24 Hoechst Ag Renin-hemmende aminosaeurederivate
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
DE3839126A1 (de) 1988-11-19 1990-05-23 Hoechst Ag Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9005318D0 (en) 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
AU2228992A (en) 1991-07-08 1993-02-11 Glaxo Group Limited Thiazolidine derivatives and their use as anti-viral compounds
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
DE69310367T2 (de) 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5514694A (en) 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5294621A (en) 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5693847A (en) 1995-04-19 1997-12-02 Vertex Pharmaceuticals Incorporated Heteroatom functionalized α-methyl ketones
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
SE9600769D0 (sv) 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US5874449A (en) 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US20020169101A1 (en) 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
CN1370170A (zh) * 1999-05-25 2002-09-18 宾夕法尼亚州研究基金会 Dna甲基转移酶抑制剂
HRP20020220A2 (en) 1999-09-14 2004-02-29 Aventis Pharmaceuticals Thienoisoxazolyl- and thienilpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
US7125903B1 (en) 1999-09-14 2006-10-24 Aventis Pharmaceuticals Inc. Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
WO2001019821A1 (en) 1999-09-14 2001-03-22 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists
US7253165B2 (en) 1999-09-14 2007-08-07 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
JP4009460B2 (ja) 2000-03-14 2007-11-14 アクテリオン ファマシューティカルズ リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
WO2002014277A1 (en) 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
IL157093A0 (en) * 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
CN101068772A (zh) 2001-07-11 2007-11-07 艾伦药物公司 N－(3－氨基－2－羟基－丙基)取代烷基酰胺化合物
WO2003018017A1 (en) 2001-08-27 2003-03-06 Arpida Ag 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
GEP20074171B (en) 2001-11-08 2007-07-25 Elan Pharm Inc N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US7338969B2 (en) 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US8013014B2 (en) 2002-07-05 2011-09-06 Georgia Tech Research Corporation Aza-peptide epoxides
JP4712384B2 (ja) 2002-09-09 2011-06-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｏｒｌ−１受容体介在障害の治療に有用なヒドロキシアルキル置換１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
EP1603884A4 (en) 2003-02-28 2008-05-28 Encysive Pharmaceuticals Inc PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE AND NAPHTHALENE UROTENSIN II RECEPTOR ANTAGONISTS
WO2004078731A1 (en) * 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
US7408008B2 (en) 2003-12-09 2008-08-05 Janssen Pharmaceutica, N.V. Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2005087752A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
RU2266906C1 (ru) * 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
WO2005118543A1 (ja) 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US20060009510A1 (en) 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP2009500437A (ja) 2005-07-11 2009-01-08 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
GB0516723D0 (en) 2005-08-15 2005-09-21 Novartis Ag Organic compounds
WO2007048042A2 (en) 2005-10-21 2007-04-26 University Of Alabama At Birmingham Small molecule inhibitors of hiv-1 capsid assembly
NZ570844A (en) 2006-02-28 2011-11-25 Helicon Therapeutics Inc Therapeutic piperazines as PDE4 inhibitors
CA2645556C (en) 2006-03-16 2016-05-24 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20090298155A1 (en) 2006-05-05 2009-12-03 Azim Surani Epigenetic Regulatory Complex for Control of Gene Expression
WO2008063842A2 (en) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
CN101012223A (zh) 2006-11-13 2007-08-08 西安新安医药科技有限公司 用于治疗的奥硝唑衍生物、制备方法及用途
ATE547411T1 (de) 2006-12-04 2012-03-15 Jiangsu Simcere Pharmaceutical R & D Co Ltd 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon
CN101157929B (zh) * 2007-02-02 2012-05-23 中国科学院上海有机化学研究所 番红霉素的生物合成基因簇
US20090099157A1 (en) 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008123582A1 (ja) * 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
WO2008145398A1 (en) 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
EP2150626B1 (en) 2007-06-07 2015-09-30 Haplomic Technologies Pty Ltd. Epigenetic methods
CN101801419A (zh) 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
US20090093493A1 (en) 2007-10-09 2009-04-09 Francesco Berardi 1-phenylalcoxy-2-beta-phenylethyl derivatives as p-glycoprotein (p-gp) inhibitors useful in drug resistance events
GB2455176A (en) 2007-11-01 2009-06-03 Acucela Inc Amine derivatives useful for treating ophthalmic diseases and disorders
WO2009059225A2 (en) 2007-11-02 2009-05-07 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
RU2371444C1 (ru) * 2008-01-24 2009-10-27 Андрей Александрович Иващенко ФУРО- И ТИЕНО[2,3-b]-ХИНОЛИН-2-КАРБОКСАМИДЫ, СПОСОБ ПОЛУЧЕНИЯ И ПРОТИВОТУБЕРКУЛЕЗНАЯ АКТИВНОСТЬ
WO2009126782A1 (en) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
FR2933977B1 (fr) * 2008-07-18 2013-04-26 Centre Nat Rech Scient Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives
KR101395952B1 (ko) 2008-09-05 2014-05-21 어큐셀라 인코포레이티드 안과 질환 및 장애 치료를 위한 황-연결 화합물
CN102197023B (zh) 2008-10-22 2015-12-16 奥克塞拉有限公司 治疗眼科疾病和紊乱的化合物
WO2010057101A2 (en) 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
BRPI1014125A2 (pt) 2009-03-17 2016-04-12 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto.
US8309547B2 (en) 2009-04-28 2012-11-13 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
US9163330B2 (en) 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US20110177105A1 (en) * 2010-01-15 2011-07-21 Roman Lopez Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
EP2630143B1 (en) 2010-10-18 2017-11-29 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
WO2012054896A1 (en) 2010-10-22 2012-04-26 Biotime Inc. Methods of modifying transcriptional regulatory networks in stem cells
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
JP2014508537A (ja) 2011-03-25 2014-04-10 アルマック・サイエンシーズ・（スコットランド）・リミテッド 酵素アッセイ
NZ618062A (en) 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
EP3208615B1 (en) 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
SG10201602144PA (en) 2011-10-03 2016-04-28 Celmatix Inc Methods and devices for assessing risk to a putative offspring of developing a condition
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
US10214476B2 (en) 2011-12-30 2019-02-26 Ecole Nationale Superieure De Chimie De Clermont Ferrand Pain relief compounds
JP6450673B2 (ja) 2012-04-03 2019-01-09 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ 幹細胞微粒子
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
WO2014013258A1 (en) 2012-07-19 2014-01-23 Reneuron Limited Stem cell microparticles
US9585891B2 (en) 2012-09-25 2017-03-07 Merck Patent Gmbh Alpha hydroxy amides
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
EP2925301A4 (en) 2012-11-29 2016-06-01 Penn State Res Found THERAPEUTIC PRODUCT AND ANTI-CANCER IMMUNOMODULATOR DHS1P PHOTODYNAMIC
CA2894230A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
KR20160003647A (ko) 2013-03-15 2016-01-11 에피자임, 인코포레이티드 Carm1 억제제 및 이의 용도
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
CN105163727B (zh) 2013-05-03 2018-08-17 豪夫迈·罗氏有限公司 刺激神经发生的异喹啉衍生物
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP6559719B2 (ja) 2014-06-25 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044569A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044650A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
JP2017530959A (ja) 2014-09-17 2017-10-19 エピザイム，インコーポレイティド Ｃａｒｍ１阻害剤およびその使用
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
US20170291905A1 (en) 2014-09-17 2017-10-12 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112017017032A2 (pt) 2015-02-11 2018-04-10 Basilea Pharmaceutica International AG derivados de mono e poliazanaftaleno substituídos e uso dos mesmos
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
GB201704476D0 (en) 2017-03-21 2017-05-03 Antabio Sas Chemical compounds

Also Published As

Publication number Publication date
US10391089B2 (en) 2019-08-27
CA2894228C (en) 2021-08-17
HRP20182037T1 (hr) 2019-02-08
US9365519B2 (en) 2016-06-14
US20170027935A1 (en) 2017-02-02
JP2016505596A (ja) 2016-02-25
AU2018202150B2 (en) 2019-07-11
EP4219465A2 (en) 2023-08-02
IL239296B (en) 2018-10-31
US20210308121A1 (en) 2021-10-07
WO2014100719A2 (en) 2014-06-26
DOP2015000158A (es) 2015-11-30
CN105452226B (zh) 2017-09-12
MX2015008052A (es) 2016-08-18
MX375184B (es) 2025-03-06
US20180303822A1 (en) 2018-10-25
IL239296A0 (en) 2015-07-30
SI2935222T1 (sl) 2019-02-28
AU2018202150A1 (en) 2018-04-19
HUE040323T2 (hu) 2019-02-28
PH12015501351B1 (en) 2015-09-07
EP3498701B1 (en) 2023-02-22
US8993555B2 (en) 2015-03-31
BR112015014590A2 (pt) 2017-11-21
ZA201505212B (en) 2016-10-26
IL267364A (en) 2019-08-29
EP2935222B1 (en) 2018-09-05
CA2894228A1 (en) 2014-06-26
US20150344434A1 (en) 2015-12-03
CN105452226A (zh) 2016-03-30
US20180098987A1 (en) 2018-04-12
US9675614B2 (en) 2017-06-13
PE20151501A1 (es) 2015-11-08
US20190343826A1 (en) 2019-11-14
EP2935222A2 (en) 2015-10-28
CL2015001790A1 (es) 2015-09-21
EA201590975A1 (ru) 2016-01-29
JP6678455B2 (ja) 2020-04-08
US10307413B2 (en) 2019-06-04
UA118548C2 (uk) 2019-02-11
EP3498701A1 (en) 2019-06-19
US20150252031A1 (en) 2015-09-10
PL2935222T3 (pl) 2019-02-28
ES2701069T3 (es) 2019-02-20
EP4219465A3 (en) 2023-09-27
EA027908B1 (ru) 2017-09-29
IL260876B (en) 2019-07-31
CY1121625T1 (el) 2020-07-31
HK1212690A1 (en) 2016-06-17
BR112015014590B1 (pt) 2022-12-20
SMT201800669T1 (it) 2019-01-11
US10980794B2 (en) 2021-04-20
PH12015501351A1 (en) 2015-09-07
PH12019500163A1 (en) 2020-11-16
KR20150112953A (ko) 2015-10-07
WO2014100719A3 (en) 2014-08-14
LT2935222T (lt) 2018-12-27
US20140329794A1 (en) 2014-11-06
US9604930B2 (en) 2017-03-28
KR102024417B1 (ko) 2019-11-07
US20200022973A1 (en) 2020-01-23
KR20190109573A (ko) 2019-09-25
PT2935222T (pt) 2018-12-10
DK2935222T3 (en) 2019-01-07
KR102173874B1 (ko) 2020-11-05
US20170334861A1 (en) 2017-11-23
MY199894A (en) 2023-11-27
RS58040B1 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
CR20150371A (es) Inhibidores de prmt5 y sus usos
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CU20110207A7 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY36123A (es) Derivados de carboxamida
UY33348A (es) Compuestos de furopiridina y usos de los mismos
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos